Currently, GLP‐1 receptor agonists, such as liraglutide and semaglutide, effectively mimic the effects of GLP‐1 to regulate energy metabolism and exhibit therapeutic role in the treatment of diabetes and obesity [24, 45]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.